Molbio Diagnostics IPO has received a measured response on Day 2, with the ₹939.70 crore issue subscribed around 1.3 times, while the QIB, NII and retail portions have all been fully booked. The IPO opened on August 10 and closes on August 12, 2026, giving investors one more day to assess the company’s business model, financial performance, valuation and risks before the issue closes. With a price band of ₹768 to ₹807 per share, the focus now shifts from initial demand to whether the subscription momentum can strengthen further on the final day.
Molbio Diagnostics IPO: Key Details
Molbio Diagnostics has fixed the IPO price band at ₹768 to ₹807 per equity share. The issue is scheduled to remain open until August 12, with the shares proposed to list on the BSE and NSE.
The company is looking to raise approximately ₹939.70 crore through the public issue. The IPO comprises a fresh issue of around ₹200 crore and an offer for sale of approximately 1.26 crore shares.
At the upper price band of ₹807, one retail lot of 18 shares requires an investment of ₹14,526.
The subscription figures on Day 2 are important because they show that demand has crossed the total shares available for subscription. However, subscription numbers alone do not tell investors whether the IPO is attractively valued.
What Is Driving Interest in the Molbio IPO?
Molbio Diagnostics operates in the point-of-care molecular diagnostics segment. Its key technology platform, Truenat, is designed to enable molecular testing closer to the patient rather than requiring every test to be conducted in a large central laboratory.
This model is particularly relevant in areas where laboratory infrastructure may be limited.
The company has developed Truenat as a portable, battery-operated PCR platform. Its diagnostic ecosystem includes testing equipment and consumables, creating a business model in which the installed testing base can generate recurring demand for test kits.
The company says its Truenat platform is patented in more than 100 countries and is designed for decentralised testing.
Day 2 Subscription: What Does 1.3x Mean?
An IPO subscribed 1.3 times means investors have submitted bids for shares equivalent to roughly 1.3 times the number of shares available in the issue.
More importantly, the reported Day 2 data indicates that all three major investor categories have crossed the 1x mark. This includes qualified institutional buyers, non-institutional investors and retail investors.
For the company, this indicates that the IPO has attracted sufficient demand before the final day.
For investors, however, it is worth remembering that an IPO can be fully subscribed and still perform differently after listing. Subscription demand needs to be considered alongside earnings, valuation, business concentration and future growth prospects.
Molbio’s Financial Performance
Molbio’s financial performance is one of the important factors behind investor interest.
According to figures available from the company’s IPO documents, revenue from operations stood at about ₹1,020.42 crore in FY25, while restated profit for the year was approximately ₹138.58 crore.
More recent FY26 figures indicate that total income increased to around ₹1,455 crore, while profit after tax rose to approximately ₹164 crore.
This means the company is already profitable rather than being an early-stage healthcare company dependent entirely on future commercialisation.
At the same time, investors should examine whether the pace of earnings growth can continue after the IPO. A high-growth healthcare technology business can command a premium valuation, but that premium ultimately needs to be supported by future earnings and cash flows.
Where Will Molbio Use the IPO Funds?
The fresh issue component is intended primarily for expansion and infrastructure.
The company plans to use funds towards capital expenditure for its research and development infrastructure, including a Centre of Excellence and connected office space.
It also plans to invest in plant, machinery and other equipment for its manufacturing facilities.
This is an important distinction between the fresh issue and the offer for sale. Money raised through the fresh issue goes to the company, while proceeds from shares sold through the OFS go to the selling shareholders.
The IPO therefore provides Molbio with additional capital to expand its research, manufacturing and product capabilities.
The Bigger Opportunity in Molecular Diagnostics
Healthcare diagnostics is changing as testing becomes faster, more decentralised and increasingly technology-driven.
Traditional diagnostic models often require samples to be transported to central laboratories. Point-of-care molecular diagnostics can potentially shorten this process by allowing testing closer to where patients receive care.
For countries and regions with limited laboratory infrastructure, this can be particularly relevant.
Molbio’s international presence also provides a route for growth outside India. Its Truenat platform is designed for use in resource-constrained settings, giving the company exposure to global public health programmes as well as commercial healthcare markets.
However, converting technological capability into sustained revenue growth depends on regulatory approvals, customer adoption, procurement cycles and continued investment in product development.
Valuation Needs Close Attention
One of the most important questions around the Molbio Diagnostics IPO is valuation.
At the upper price band of ₹807, the company is being valued at a substantial multiple of its earnings. Based on FY26 earnings figures, market commentary has placed the IPO valuation at around 54.6 times earnings.
That does not automatically make the IPO unattractive, but it raises the level of growth investors may expect from the business.
A company operating in a specialised healthcare technology segment can justify a higher valuation if it delivers strong and consistent earnings growth. But if growth slows, a high starting valuation can leave less room for disappointment.
This is why investors should assess the IPO beyond its Day 2 subscription figure.
Key Risks Investors Should Consider
Molbio’s business also has specific risks.
One concern is customer concentration. Government agencies and international aid organisations reportedly contributed a significant portion of finished-goods revenue in FY26. This makes procurement cycles and public health programmes important factors for revenue visibility.
There is also product concentration. TB-related diagnostic products account for a significant share of finished-goods sales, making diversification an important factor to monitor.
Working capital is another consideration. Higher receivables can increase the time between making a sale and receiving cash.
The company’s borrowings also increased significantly in FY26 compared with the previous year, which means investors should monitor debt and cash generation alongside profit growth.
What Should Investors Watch on Day 3?
The final day of the Molbio Diagnostics IPO will be important for understanding the strength of overall demand.
Investors should particularly watch the QIB subscription because institutional participation can provide useful insight into market demand, although it should not be treated as a recommendation.
The final subscription number, category-wise demand and any changes in the grey market premium may attract attention before the issue closes.
However, grey market premium is unofficial and can change rapidly. It should not be used as a substitute for analysing the company’s financial statements and IPO valuation.
Molbio Diagnostics IPO: What Investors Should Take Away
The Day 2 subscription of around 1.3x indicates that the Molbio Diagnostics IPO has received enough demand to cross the basic subscription threshold. The company also has several characteristics that investors may find relevant, including a specialised molecular diagnostics platform, an established product ecosystem and a profitable operating history.
But there are equally important questions around valuation, customer concentration, product concentration, working capital and debt.
The IPO is therefore not simply a story about subscription numbers. The bigger question is whether Molbio can continue growing its diagnostics platform and earnings at a rate that supports the valuation investors are paying today.
Conclusion
Molbio Diagnostics IPO has crossed the 1x subscription mark on Day 2, with the issue subscribed around 1.3 times and QIB, NII and retail categories fully booked.
The company operates in a specialised healthcare technology segment through its Truenat point-of-care molecular diagnostics platform. Its profitability and plans to invest in R&D and manufacturing provide a foundation for future growth.
At the same time, the IPO comes at a valuation that requires investors to have confidence in sustained earnings growth. Customer and product concentration, working capital requirements and debt are additional factors that need attention.
With the issue closing on August 12, the final subscription figures will provide a clearer picture of investor demand. For long-term investors, however, the more important test will be whether Molbio can turn its technology and existing market presence into consistent revenue, profit and cash-flow growth after listing.
Frequently Asked Questions
1. What is the Molbio Diagnostics IPO Day 2 subscription status?
The Molbio Diagnostics IPO was subscribed around 1.3 times on Day 2, with the QIB, NII and retail categories fully booked.
2. When does the Molbio Diagnostics IPO close?
The Molbio Diagnostics IPO closes on August 12, 2026. The issue opened for subscription on August 10.
3. What is the Molbio Diagnostics IPO price band?
The price band has been fixed at ₹768 to ₹807 per equity share.
4. What is the minimum investment in the Molbio Diagnostics IPO?
The minimum retail application is for 18 shares. At the upper price band of ₹807, the minimum investment is ₹14,526.
5. What is the size of the Molbio Diagnostics IPO?
The IPO is expected to raise approximately ₹939.70 crore. It includes a fresh issue of around ₹200 crore and an offer for sale of approximately 1.26 crore shares.
6. What does Molbio Diagnostics do?
Molbio Diagnostics develops point-of-care molecular diagnostic technologies. Its Truenat platform is designed to enable decentralised molecular testing for various diseases.
7. What is the main product of Molbio Diagnostics?
Truenat is Molbio’s key molecular diagnostics platform. It uses a portable PCR-based system designed to provide testing closer to the point of care.
8. What will Molbio Diagnostics do with the IPO proceeds?
The fresh issue proceeds are planned for capital expenditure related to R&D infrastructure, a Centre of Excellence, office space, manufacturing equipment and other plant and machinery.
9. What are the major risks in the Molbio Diagnostics IPO?
Key risks include valuation, customer concentration, dependence on certain diagnostic products, working capital requirements, debt levels and the need to sustain product adoption and earnings growth.
10. Should investors apply for the Molbio Diagnostics IPO?
Investors should make the decision based on their risk profile, investment horizon, valuation assessment and understanding of the company’s business. The 1.3x subscription figure or grey market premium alone should not be considered sufficient grounds for an investment decision.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.
Jaspreet Singh Arora is the Chief Investment Officer at Equentis, where he heads a seasoned team of equity analysts and turns two decades of market experience into portfolios that consistently beat the benchmark. A go-to voice on cement, building-materials, real-estate, and construction stocks, Jaspreet previously ran research desks at leading brokerages, honing an eye for the metrics that truly move share prices. His plain-spoken analysis helps investors cut through noise and act with conviction. When he’s not deep-diving into earnings calls, you’ll find him unwinding over sports, weekend cricket or a good history podcast.
